Literature DB >> 10364909

Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?

C Jorgensen1, F Apparailly, J Sany.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10364909      PMCID： PMC1752849          DOI： 10.1136/ard.58.3.136

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  34 in total

Review 1.  TNF alpha--a pivotal role in rheumatoid arthritis?

Authors:  F M Brennan; R N Maini; M Feldmann
Journal:  Br J Rheumatol       Date:  1992-05

2.  Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; H Bijl; J N Woody
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

Review 3.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

4.  Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis.

Authors:  G S Firestein; D L Boyle; C Yu; M M Paine; T D Whisenand; N J Zvaifler; W P Arend
Journal:  Arthritis Rheum       Date:  1994-05

5.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Authors:  C J Fisher; J F Dhainaut; S M Opal; J P Pribble; R A Balk; G J Slotman; T J Iberti; E C Rackow; M J Shapiro; R L Greenman
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

6.  Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.

Authors:  D Wendling; E Racadot; J Wijdenes
Journal:  J Rheumatol       Date:  1993-02       Impact factor: 4.666

7.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; P Katsikis; F M Brennan; J Walker; H Bijl; J Ghrayeb
Journal:  Arthritis Rheum       Date:  1993-12

8.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Authors:  R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann
Journal:  Arthritis Rheum       Date:  1998-09

9.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

Authors:  E Abraham; R Wunderink; H Silverman; T M Perl; S Nasraway; H Levy; R Bone; R P Wenzel; R Balk; R Allred
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

10.  Immunoregulatory role of interleukin 10 in rheumatoid arthritis.

Authors:  P D Katsikis; C Q Chu; F M Brennan; R N Maini; M Feldmann
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307
View more
  2 in total

1.  A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha.

Authors:  K Mihara; C Almansa; R L Smeets; E E M G Loomans; J Dulos; P M F Vink; M Rooseboom; H Kreutzer; F Cavalcanti; A M Boots; R L Nelissen
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

2.  Biologic agents for the treatment of juvenile rheumatoid arthritis: current status.

Authors:  Ruy Carrasco; Judith A Smith; Daniel Lovell
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.